The use of bone-turnover markers in asia-pacific populations
Bone-turnover marker (BTM) measurements in the blood or urine reflect the bone-remodeling rate and may be useful for studying and clinically managing metabolic bone diseases. Substantial evidence supporting the diagnostic use of BTMs has accumulated in recent years, together with the publication of...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Korean Society for Laboratory Medicine
2023
|
| Online Access: | http://psasir.upm.edu.my/id/eprint/117075/ http://psasir.upm.edu.my/id/eprint/117075/1/117075.pdf |
| _version_ | 1848867160283152384 |
|---|---|
| author | Vasikaran, Samuel Thambiah, Subashini C. Tan, Rui Zhen Loh, Tze Ping |
| author_facet | Vasikaran, Samuel Thambiah, Subashini C. Tan, Rui Zhen Loh, Tze Ping |
| author_sort | Vasikaran, Samuel |
| building | UPM Institutional Repository |
| collection | Online Access |
| description | Bone-turnover marker (BTM) measurements in the blood or urine reflect the bone-remodeling rate and may be useful for studying and clinically managing metabolic bone diseases. Substantial evidence supporting the diagnostic use of BTMs has accumulated in recent years, together with the publication of several guidelines. Most clinical trials and observational and reference-interval studies have been performed in the Northern Hemisphere and have mainly involved Caucasian populations. This review focuses on the available data for populations from the Asia-Pacific region and offers guidance for using BTMs as diagnostic biomarkers in these populations. The procollagen I N-terminal propeptide and β-isomerized C-terminal telopeptide of type-I collagen (measured in plasma) are reference BTMs used for investigating osteoporosis in clinical settings. Premenopausal reference intervals (established for use with Asia-Pacific populations) and reference change values and treatment targets (used to monitor osteoporosis treatment) help guide the management of osteoporosis. Measuring BTMs that are not affected by renal failure, such as the bone-specific isoenzyme alkaline phosphatase and tartrate-resistant acid phosphatase 5b, may be advantageous for patients with advanced chronic kidney disease. Further studies of the use of BTMs in individuals with metabolic bone disease, coupled with the harmonization of commercial assays to provide equivalent results, will further enhance their clinical applications. |
| first_indexed | 2025-11-15T14:32:05Z |
| format | Article |
| id | upm-117075 |
| institution | Universiti Putra Malaysia |
| institution_category | Local University |
| language | English |
| last_indexed | 2025-11-15T14:32:05Z |
| publishDate | 2023 |
| publisher | Korean Society for Laboratory Medicine |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | upm-1170752025-04-25T01:59:10Z http://psasir.upm.edu.my/id/eprint/117075/ The use of bone-turnover markers in asia-pacific populations Vasikaran, Samuel Thambiah, Subashini C. Tan, Rui Zhen Loh, Tze Ping Bone-turnover marker (BTM) measurements in the blood or urine reflect the bone-remodeling rate and may be useful for studying and clinically managing metabolic bone diseases. Substantial evidence supporting the diagnostic use of BTMs has accumulated in recent years, together with the publication of several guidelines. Most clinical trials and observational and reference-interval studies have been performed in the Northern Hemisphere and have mainly involved Caucasian populations. This review focuses on the available data for populations from the Asia-Pacific region and offers guidance for using BTMs as diagnostic biomarkers in these populations. The procollagen I N-terminal propeptide and β-isomerized C-terminal telopeptide of type-I collagen (measured in plasma) are reference BTMs used for investigating osteoporosis in clinical settings. Premenopausal reference intervals (established for use with Asia-Pacific populations) and reference change values and treatment targets (used to monitor osteoporosis treatment) help guide the management of osteoporosis. Measuring BTMs that are not affected by renal failure, such as the bone-specific isoenzyme alkaline phosphatase and tartrate-resistant acid phosphatase 5b, may be advantageous for patients with advanced chronic kidney disease. Further studies of the use of BTMs in individuals with metabolic bone disease, coupled with the harmonization of commercial assays to provide equivalent results, will further enhance their clinical applications. Korean Society for Laboratory Medicine 2023-10-23 Article PeerReviewed text en cc_by_nc_4 http://psasir.upm.edu.my/id/eprint/117075/1/117075.pdf Vasikaran, Samuel and Thambiah, Subashini C. and Tan, Rui Zhen and Loh, Tze Ping (2023) The use of bone-turnover markers in asia-pacific populations. Annals of Laboratory Medicine, 44 (2). pp. 126-134. ISSN 2234-3806; eISSN: 2234-3814 https://www.annlabmed.org/journal/view.html?doi=10.3343/alm.2023.0214 10.3343/alm.2023.0214 |
| spellingShingle | Vasikaran, Samuel Thambiah, Subashini C. Tan, Rui Zhen Loh, Tze Ping The use of bone-turnover markers in asia-pacific populations |
| title | The use of bone-turnover markers in asia-pacific populations |
| title_full | The use of bone-turnover markers in asia-pacific populations |
| title_fullStr | The use of bone-turnover markers in asia-pacific populations |
| title_full_unstemmed | The use of bone-turnover markers in asia-pacific populations |
| title_short | The use of bone-turnover markers in asia-pacific populations |
| title_sort | use of bone-turnover markers in asia-pacific populations |
| url | http://psasir.upm.edu.my/id/eprint/117075/ http://psasir.upm.edu.my/id/eprint/117075/ http://psasir.upm.edu.my/id/eprint/117075/ http://psasir.upm.edu.my/id/eprint/117075/1/117075.pdf |